HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Feb 2022 08:30 AM
RNS
HUTCHMED to Announce 2021 Final Results
04 Feb 2022 09:30 AM
RNS
Phase Ib/II Combination Study of HMPL-453
20 Jan 2022 07:00 AM
RNS
HUTCHMED Initiates Phase I Trial of HMPL-653
19 Jan 2022 07:00 AM
RNS
HUTCHMED Data at ASCO GI Cancers Symposium
17 Jan 2022 09:00 AM
RNS
Holding(s) in Company
12 Jan 2022 11:00 AM
RNS
Breakthrough Therapy Designation for HMPL-523
10 Jan 2022 07:00 AM
RNS
HUTCHMED Initiates Phase I Study of HMPL-760
31 Dec 2021 07:00 AM
RNS
Blocklisting Six Monthly Return
31 Dec 2021 07:00 AM
RNS
Total Voting Rights
20 Dec 2021 07:00 AM
RNS
HUTCHMED Included in FTSE Russell Indexes
15 Dec 2021 09:45 AM
RNS
Grant of Share Options and Awards under LTIP
14 Dec 2021 07:00 AM
RNS
HMPL-523 Clinical Data Presented at ASH
10 Dec 2021 10:00 AM
RNS
HUTCHMED Presents Data at ESMO Immuno-Oncology '21
06 Dec 2021 07:00 AM
RNS
HUTCHMED Completes Planned Enrollment of FRESCO-2
03 Dec 2021 07:00 AM
RNS
Updated NRDL to include ELUNATE and SULANDA
30 Nov 2021 08:30 AM
RNS
Total Voting Rights
24 Nov 2021 07:00 AM
RNS
HUTCHMED and AZ Initiate SACHI Phase 3 Trial
08 Nov 2021 07:00 AM
RNS
HUTCHMED to Present Clinical Data at ASH
01 Nov 2021 07:00 AM
RNS
HUTCHMED and AZ Initiate SAMETA Global P3 Trial
29 Oct 2021 09:30 AM
RNS
Total Voting Rights
28 Oct 2021 07:00 AM
RNS
HUTCHMED Initiates Phase III Trial of HMPL-523
20 Oct 2021 09:30 AM
RNS
Grant of Awards under Long Term Incentive Plan
30 Sep 2021 09:30 AM
RNS
Total Voting Rights
29 Sep 2021 07:00 AM
RNS
Closure of Non-Core OTC Joint Venture Divestment
29 Sep 2021 07:00 AM
RNS
HUTCHMED Highlights Presentations at CSCO 2021
21 Sep 2021 07:00 AM
RNS
HUTCHMED Initiates Phase III Trial SURTORI-01
20 Sep 2021 07:00 AM
RNS
Japan Bridging Study For Surufatinib Initiated
13 Sep 2021 07:00 AM
RNS
Breakthrough Therapy Designation for Amdizalisib
08 Sep 2021 11:30 AM
RNS
HUTCHMED and AZ Initiate Phase III Trial in China
07 Sep 2021 09:30 AM
RNS
HUTCHMED to Present Clinical Data at ESMO
06 Sep 2021 07:00 AM
RNS
HUTCHMED Shares Included in Stock Connect Programs
02 Sep 2021 12:45 PM
RNS
Grant of Share Options, and Awards under LTIP
31 Aug 2021 09:30 AM
RNS
Total Voting Rights
26 Aug 2021 07:00 AM
RNS
Phase Ib/II Trial of Fruquintinib & Tislelizumab
23 Aug 2021 07:00 AM
RNS
HUTCHMED Selected for Certain Hang Seng Indexes
17 Aug 2021 09:30 AM
RNS
ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
09 Aug 2021 07:00 AM
RNS
HUTCHMED & Epizyme Announce TAZVERIK Collaboration
30 Jul 2021 09:30 AM
RNS
Total Voting Rights
28 Jul 2021 12:00 PM
RNS
Interim Results and Business Updates
28 Jul 2021 07:00 AM
RNS
Phase II Trial of ORPATHYS Initiated
23 Jul 2021 12:01 PM
RNS
Stabilizing Actions & End of Stabilization Period
16 Jul 2021 10:50 AM
RNS
Holding(s) in Company
16 Jul 2021 07:00 AM
RNS
Surufatinib MAA Submitted and Validated by the EMA
14 Jul 2021 09:35 AM
RNS
Holding(s) in Company
13 Jul 2021 07:00 AM
RNS
First Commercial Sale of ORPATHYS® in China
12 Jul 2021 02:35 PM
RNS
Full Exercise of the Over-allotment Option
06 Jul 2021 09:30 AM
RNS
HUTCHMED Initiates Phase I Trials of HMPL-295
02 Jul 2021 11:15 AM
RNS
Holding(s) in Company
02 Jul 2021 09:30 AM
RNS
Notice of Results
01 Jul 2021 11:00 AM
RNS
US FDA Accepts NDA Filing for Surufatinib

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100